title: Sofosbuvir and ribavirin in acute hepatitis C-infected patient with decompensated cirrhosis.
abstract: BACKGROUND
  The treatment of chronic hepatitis C virus infection has been revolutionized by the advent of direct-acting antiviral agents. However, evidence of its effects on patients with acute hepatitis C (AHC) virus infection is limited.
  
  
  METHODS
  We report the case of a patient with decompensated cirrhosis induced by autoimmune liver disease, whose condition rapidly deteriorated following AHC virus infection. The patient received sofosbuvir and ribavirin combination treatment for 12 weeks. Serum hepatitis C virus RNA remained undetectable 36 weeks after discontinuing sofosbuvir and ribavirin.
  
  
  CONCLUSIONS
  Our findings support the use of sofosbuvir and ribavirin as a treatment in AHC patients with decompensated cirrhosis.
authors.affiliation: Department of Gastroenterology, Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province, China.
authors.forename: Hui
authors.initials: H
authors.lastname: Liu
authors.forename: Tong
authors.initials: T
authors.lastname: Zhang
authors.forename: Yan
authors.initials: Y
authors.lastname: Yan
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications*; D012254:Ribavirin / Q000008:administration & dosage / Q000627:therapeutic use*; D000069474:Sofosbuvir / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D012254:Ribavirin; D000069474:Sofosbuvir